{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:31:43Z","timestamp":1787315503869,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204443"],"award-info":[{"award-number":["82204443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574638"],"award-info":[{"award-number":["82574638"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["zyyzdxk-2023083"],"award-info":[{"award-number":["zyyzdxk-2023083"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.apsb.2025.12.040","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:08:11Z","timestamp":1767028091000},"page":"2317-2331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Isoalantolactone induces AML pyroptosis and potentiates \u03b1-PD-1 efficacy by targeting selenoprotein TXNRD1"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6422-5159","authenticated-orcid":false,"given":"Xiaoxuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5586-3956","authenticated-orcid":false,"given":"Yanyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1289-5943","authenticated-orcid":false,"given":"Jianqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0469-907X","authenticated-orcid":false,"given":"Wukun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.12.040_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.apsb.2025.12.040_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.2021011619","article-title":"MICA\/B antibody induces macrophage-mediated immunity against acute myeloid leukemia","volume":"139","author":"Alves da Silva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.12.040_bib3","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.apsb.2025.12.040_bib4","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603\/RATIFY trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2025.12.040_bib5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1080\/14656566.2023.2272659","article-title":"Ivosidenib in acute myeloid leukemia","volume":"24","author":"Bruzzese","year":"2023","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.apsb.2025.12.040_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115820","article-title":"Venetoclax in adult acute myeloid leukemia","volume":"168","author":"Hu","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.12.040_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.34133\/research.0169","article-title":"Acceptor engineering produces ultrafast nonradiative decay in NIR-II Aza-BODIPY nanoparticles for efficient osteosarcoma photothermal therapy via concurrent apoptosis and pyroptosis","volume":"6","author":"Shi","year":"2023","journal-title":"Research"},{"key":"10.1016\/j.apsb.2025.12.040_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-021-00487-z","article-title":"COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials","volume":"18","author":"Desai","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2025.12.040_bib9","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3389\/fimmu.2018.01274","article-title":"Increased regulatory T cells in peripheral blood of acute myeloid leukemia patients rely on tumor necrosis factor (TNF)-\u03b1\u2013TNF receptor-2 pathway","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.12.040_bib10","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2025.12.040_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","article-title":"The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators","volume":"43","author":"Binder","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.apsb.2025.12.040_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.34133\/research.0311","article-title":"Single-cell microgel encapsulation improves the therapeutic efficacy of mesenchymal stem cells in treating intervertebral disc degeneration via inhibiting pyroptosis","volume":"7","author":"Huang","year":"2024","journal-title":"Research"},{"key":"10.1016\/j.apsb.2025.12.040_bib13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/imm.12665","article-title":"Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells","volume":"149","author":"Ozkazanc","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.apsb.2025.12.040_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00262-021-02978-5","article-title":"Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis","volume":"71","author":"Liu","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2025.12.040_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2025.12.040_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.2021011619","article-title":"MICA\/B antibody induces macrophage-mediated immunity against acute myeloid leukemia","volume":"139","author":"Alves da Silva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.12.040_bib17","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S1470-2045(17)30852-5","article-title":"Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis","volume":"18","author":"Daver","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.12.040_bib18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2025.12.040_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.apsb.2025.12.040_bib20","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.3390\/molecules29133121","article-title":"Agonists and inhibitors of the cGAS\u2013STING pathway","volume":"29","author":"Yu","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.12.040_bib21","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.apsb.2025.12.040_bib22","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3389\/fimmu.2017.01918","article-title":"ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory t cells and tolerogenic dendritic cells","volume":"8","author":"Lecciso","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.12.040_bib23","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/j.apsb.2025.03.026","article-title":"Inhibition of CCT5-mediated asparagine biosynthesis and anti-PD-L1 produce synergistic antitumor effects in colorectal cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.12.040_bib24","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.4049\/jimmunol.164.12.6287","article-title":"Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function","volume":"164","author":"Junn","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.12.040_bib25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41419-024-06939-5","article-title":"Oxidative cell death in cancer: mechanisms and therapeutic opportunities","volume":"15","author":"An","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.12.040_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imr.12534","article-title":"Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases","volume":"277","author":"Man","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2025.12.040_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103277","article-title":"TrxR1 is involved in the activation of Caspase-11 by regulating the oxidative-reductive status of Trx-1","volume":"75","author":"Bai","year":"2024","journal-title":"Redox Biol"},{"key":"10.1016\/j.apsb.2025.12.040_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13046-024-03165-x","article-title":"Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy","volume":"43","author":"He","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.12.040_bib29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41419-023-06301-1","article-title":"Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with \u03b1PDL1 in ovarian cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.12.040_bib30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.34133\/research.0380","article-title":"USP18 antagonizes pyroptosis by facilitating selective autophagic degradation of gasdermin D","volume":"7","author":"Wang","year":"2024","journal-title":"Research"},{"key":"10.1016\/j.apsb.2025.12.040_bib31","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1038\/s41388-021-01924-0","article-title":"Thioredoxin reductase is a major regulator of metabolism in leukemia cells","volume":"40","author":"Karunanithi","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.12.040_bib32","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/pharmaceutics13101627","article-title":"Induction of apoptosis by isoalantolactone in human hepatocellular carcinoma Hep3B cells through activation of the ROS-dependent JNK signaling pathway","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.12.040_bib33","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3892\/or.2015.4461","article-title":"Isoalantolactone induces autophagic cell death in SKOV3 human ovarian carcinoma cells via upregulation of PEA-15","volume":"35","author":"Weng","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.apsb.2025.12.040_bib34","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1002\/ptr.8132","article-title":"Isoalantolactone exerts anti-melanoma effects via inhibiting PI3K\/AKT\/mTOR and STAT3 signaling in cell and mouse models","volume":"38","author":"Li","year":"2024","journal-title":"Phytother Res"},{"key":"10.1016\/j.apsb.2025.12.040_bib35","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/15384101.2023.2209963","article-title":"Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin","volume":"22","author":"Yin","year":"2023","journal-title":"Cell Cycle"},{"key":"10.1016\/j.apsb.2025.12.040_bib36","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3892\/or.2016.4954","article-title":"Isoalantolactone inhibits the migration and invasion of human breast cancer MDA-MB-231 cells via suppression of the p38 MAPK\/NF-\u03baB signaling pathway","volume":"36","author":"Wang","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.apsb.2025.12.040_bib37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13046-018-0987-9","article-title":"Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells","volume":"37","author":"Chen","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.12.040_bib38","first-page":"44","article-title":"Oxidative stress and cellular senescence: roles in tumor progression and therapeutic opportunities","volume":"3","author":"Jin","year":"2024","journal-title":"MedComm Oncol"},{"key":"10.1016\/j.apsb.2025.12.040_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.critrevonc.2015.10.001","article-title":"Constitutive NF-\u03baB activation in AML: causes and treatment strategies","volume":"98","author":"Bosman","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.apsb.2025.12.040_bib40","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2025.12.040_bib41","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/ijms21082907","article-title":"The PI3K\u2013Akt\u2013mTOR signaling pathway in human acute myeloid leukemia (AML) cells","volume":"21","author":"Nepstad","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.12.040_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102351","article-title":"Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma","volume":"54","author":"Xu","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.apsb.2025.12.040_bib43","article-title":"Protocol for assaying irreversible inhibitors of thioredoxin reductase 1","volume":"5","author":"Sun","year":"2024","journal-title":"STAR Protoc"},{"key":"10.1016\/j.apsb.2025.12.040_bib44","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1111\/febs.17301","article-title":"Thioredoxin reductase inhibition and glutathione depletion mediated by glaucocalyxin A promote intracellular disulfide stress in gastric cancer cells","volume":"291","author":"Wang","year":"2024","journal-title":"FEBS J"},{"key":"10.1016\/j.apsb.2025.12.040_bib46","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.tips.2017.06.001","article-title":"Targeting the thioredoxin system for cancer therapy","volume":"38","author":"Zhang","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2025.12.040_bib47","doi-asserted-by":"crossref","first-page":"127ra38","DOI":"10.1126\/scitranslmed.3003562","article-title":"Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein","volume":"4","author":"Zhen","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.12.040_bib48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.freeradbiomed.2022.01.019","article-title":"Inhibition of thioredoxin reductase by natural anticancer candidate \u03b2-lapachone accounts for triggering redox activation-mediated HL-60 cell apoptosis","volume":"180","author":"Zhang","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.apsb.2025.12.040_bib49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.12.040_bib50","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1097\/CM9.0000000000001628","article-title":"Oxidative stress in leukemia and antioxidant treatment","volume":"134","author":"Dong","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.apsb.2025.12.040_bib51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni.2283","article-title":"Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps\u2013SHP-2 pathway","volume":"13","author":"Xu","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2025.12.040_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115293","article-title":"\u03b2-HB treatment reverses sorafenib resistance by shifting glycolysis-lactate metabolism in HCC","volume":"166","author":"Suk","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.12.040_bib53","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1016\/j.apsb.2024.06.026","article-title":"Pyroptosis: induction and inhibition strategies for immunotherapy of diseases","volume":"14","author":"Wu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.12.040_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216676","article-title":"PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation","volume":"586","author":"Hu","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2025.12.040_bib55","article-title":"Immunotherapy for gastric cancer: advances and challenges","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm Onco"},{"key":"10.1016\/j.apsb.2025.12.040_bib56","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","article-title":"Pyroptosis: mechanisms and diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2025.12.040_bib57","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00277-016-2915-4","article-title":"Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms","volume":"96","author":"Choi","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.apsb.2025.12.040_bib58","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1136\/gutjnl-2021-326350","article-title":"PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma","volume":"71","author":"Lu","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.apsb.2025.12.040_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.12.040_bib60","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/antiox11040710","article-title":"Piperlongumine inhibits thioredoxin reductase 1 by targeting selenocysteine residues and sensitizes cancer cells to erastin","volume":"11","author":"Yang","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.apsb.2025.12.040_bib61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-pharmtox-052220-102509","article-title":"Thioredoxin reductase inhibition for cancer therapy","volume":"62","author":"Gencheva","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.apsb.2025.12.040_bib62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2021.12.314","article-title":"Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling","volume":"180","author":"Zhang","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.apsb.2025.12.040_bib64","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.freeradbiomed.2020.01.008","article-title":"Sanguinarine as a new chemical entity of thioredoxin reductase inhibitor to elicit oxidative stress and promote tumor cell apoptosis","volume":"152","author":"Yao","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.apsb.2025.12.040_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101686","article-title":"Au4 cluster inhibits human thioredoxin reductase activity via specifically binding of Au to Cys189","volume":"47","author":"Du","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.apsb.2025.12.040_bib65","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41419-019-2035-x","article-title":"ROS-mediated inactivation of the PI3K\/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin","volume":"10","author":"Wen","year":"2019","journal-title":"Cell Death Dis"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525008482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525008482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T19:38:05Z","timestamp":1779824285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525008482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2211383525008482"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.12.040","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isoalantolactone induces AML pyroptosis and potentiates \u03b1-PD-1 efficacy by targeting selenoprotein TXNRD1","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}